Homology Medicines Inc (NASDAQ:FIXX) Shares Bought by Marshall Wace LLP

Marshall Wace LLP boosted its stake in shares of Homology Medicines Inc (NASDAQ:FIXX) by 470.8% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 15,241 shares of the company’s stock after purchasing an additional 12,571 shares during the quarter. Marshall Wace LLP’s holdings in Homology Medicines were worth $298,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in FIXX. TD Asset Management Inc. boosted its stake in Homology Medicines by 15.8% during the first quarter. TD Asset Management Inc. now owns 27,868 shares of the company’s stock worth $773,000 after buying an additional 3,800 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in shares of Homology Medicines in the 1st quarter valued at $2,582,000. Global Thematic Partners LLC lifted its stake in shares of Homology Medicines by 32.2% in the 2nd quarter. Global Thematic Partners LLC now owns 218,491 shares of the company’s stock valued at $4,276,000 after purchasing an additional 53,164 shares during the last quarter. Strs Ohio acquired a new position in shares of Homology Medicines in the 2nd quarter valued at $219,000. Finally, Aperio Group LLC acquired a new position in shares of Homology Medicines in the 2nd quarter valued at $34,000. 68.09% of the stock is currently owned by institutional investors.

In related news, COO Siyamak Rasty sold 8,000 shares of the stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $20.00, for a total transaction of $160,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO W Bradford Smith sold 6,000 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.37, for a total value of $104,220.00. Following the transaction, the chief financial officer now directly owns 6,000 shares in the company, valued at approximately $104,220. The disclosure for this sale can be found here. In the last three months, insiders have sold 92,566 shares of company stock worth $1,670,800. 33.40% of the stock is owned by corporate insiders.

Shares of Homology Medicines stock opened at $17.19 on Friday. Homology Medicines Inc has a 52 week low of $14.19 and a 52 week high of $31.80. The business’s fifty day simple moving average is $19.02 and its 200-day simple moving average is $20.77. The firm has a market cap of $756.22 million, a PE ratio of -8.60 and a beta of 0.09.

Homology Medicines (NASDAQ:FIXX) last posted its earnings results on Thursday, August 8th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.06). Homology Medicines had a negative return on equity of 38.74% and a negative net margin of 3,232.67%. The firm had revenue of $0.39 million for the quarter, compared to analyst estimates of $1.00 million. On average, research analysts expect that Homology Medicines Inc will post -2.27 earnings per share for the current year.

Several equities analysts have recently commented on the company. Robert W. Baird assumed coverage on Homology Medicines in a research note on Monday, September 9th. They issued an “outperform” rating and a $30.00 price target on the stock. Canaccord Genuity set a $37.00 price target on Homology Medicines and gave the company a “buy” rating in a research note on Friday, July 26th. Zacks Investment Research raised Homology Medicines from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. Finally, HC Wainwright set a $36.00 price target on Homology Medicines and gave the company a “buy” rating in a research note on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Homology Medicines presently has a consensus rating of “Buy” and an average target price of $31.40.

Homology Medicines Company Profile

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Read More: Net Asset Value

Want to see what other hedge funds are holding FIXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Homology Medicines Inc (NASDAQ:FIXX).

Institutional Ownership by Quarter for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.